Assessing the Pharmacological Effects of a GPR65 Antagonist in a PDX Model of Clear Cell Renal Carcinoma
Time: 10:00 am
day: Day Two
Details:
- Introduction to the pH sensing GPCR GPR65 as a genetically validated IO target
- PDX model selection based on biological rationale, gene expression profiling and characterisation of the TME
- Assessment of the effects of an orally administered GPR65 antagonist in a PDX model of clear cell renal carcinoma
